MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural Effusion

An abnormal accumulation of fluid in the pleural space.

Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

PLoS One 2017 October [Link] Otoshi T, Kataoka Y, Ikegaki S, Saito E, Matsumoto H, Kaku S, Shimada M, Hirabayashi M Abstract In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of […]

Comments Off on Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Cancer Immunology, immunotherapy [Epub 2017 March 13] [Link] Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U Abstract Malignant pleural effusions are frequent in patients with advanced stages of lung cancer and are commonly infiltrated by lymphocytes and tumor cells. CD8+ T cells from these effusions have reduced effector functions. The programmed death receptor 1(PD-1)/programmed death […]

Comments Off on The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Assessment of patient-reported outcome measures in pleural interventions

BMJ Open Respiratory Research 2017 July [Link] Psallidas I, Yousuf A, Talwar A, Hallifax RJ, Mishra EK, Corcoran JP, Ali N, Rahman NM Abstract INTRODUCTION: There is a lack of data evaluating the clinical effect on symptoms of pleural intervention procedures. This has led to the development of patient-reported outcome measures (PROMs) to define what […]

Comments Off on Assessment of patient-reported outcome measures in pleural interventions

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Oncotarget 2017 May [Link] Lagniau S, Lamote K, van Meerbeeck JP, Vermaelen KY Abstract Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes curative treatment. We assume that only new and non-invasive biomarkers allowing earlier detection will result in better patient […]

Comments Off on Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Diagnostic value of medical thoracoscopy in malignant pleural effusion

BMC Pulmonary Medicine 2017 August [Link] Wu YB, Xu LL, Wang XJ, Wang Z, Zhang J, Tong ZH, Shi HZ Abstract BACKGROUND: Medical thoracoscopy has been shown to be an efficacious procedure in diagnosing unexplained exudative pleural effusions with excellent safety. This study aimed to assess the diagnostic significance of thoracoscopy in the management of […]

Comments Off on Diagnostic value of medical thoracoscopy in malignant pleural effusion

Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases

Case Reports in Oncological Medicine 2017 [Epub 2017 May 29] [Link] Ideguchi R, Ashizawa K, Akashi S, Shindo M, Minami K, Fukuda T, Irie J, Fukuda M, Uetani M Abstract We herein report two cases of malignant pleural mesothelioma with marked lymphangiosis. The patients included a 68-year-old man and a 67-year-old man who both had […]

Comments Off on Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases

Chest pain and recurrent chylothorax: an unusual presentation of malignant pleural mesothelioma.

Respirology Case Reports 2017 June [Link] Darley DR, Granger E, Glanville AR Abstract Malignant mesothelioma presenting with recurrent chylous effusion is rare. We describe the case of a 34-year-old female Macedonian immigrant who presented with central chest pain and subsequently a left-sided chylous pleural effusion. The diagnosis was made on pleural biopsy via video-assisted thoracoscopic […]

Comments Off on Chest pain and recurrent chylothorax: an unusual presentation of malignant pleural mesothelioma.

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Oncotarget 2017 May 17 [Epub ahead of print] [Link] Lagniau S, Lamote K, van Meerbeeck JP2, Vermaelen KY Abstract Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes curative treatment. We assume that only new and non-invasive biomarkers allowing earlier detection […]

Comments Off on Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report

Cell Oncology 2017 June 2 [Epub ahead of print] [Link] Beije N, Kraan J, den Bakker MA, Maat APWM, van der Leest C, Cornelissen R, Van NM, Martens JWM, Aerts JGJV, Sleijfer S Abstract PURPOSE: There is a lack of robust and clinically utilizable markers for the diagnosis and prognostication of malignant pleural mesothelioma (MPM). […]

Comments Off on Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Respiratory Research 2017 April [Link] Cortes-Dericks L, Schmid RA Abstract Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient […]

Comments Off on CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.